Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Uncover Which Aristocrats Etf Grows Fastest and learn which factors power rapid growth, helping you make informed investment decisions.
20,959 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Red Cat Holdings posted a record Q4 revenue of $26.2 million and full-year $40.7 million, but margins stayed thin and...
When a company's CFO divests shares amid a strong stock run, investors want to know what it means. This deep dive exp...
The Department of Justice confirmed an active antitrust inquiry into the U.S. beef industry, targeting major meatpack...
Li Lu’s Himalaya Capital places a near alarmingly large bet on Alphabet, powering a dramatic year for the fund and re...
Dogecoin broke through a multi-session resistance with a heavy volume burst, prompting traders to eye the next hurdle...
Federal investigators say UCLA's David Geffen School of Medicine used race in admissions in ways that violated civil ...
Dive into comstock (crk) 2026 earnings with a clear, earnings-call-driven view. We unpack Q1 results, cash flow dynam...
XRP is carving a large pennant as traders eye a potential breakout this week. With volume shrinking, a move past $1.6...
A practical, plain‑language breakdown of Navigator NVGS's Q1 2026 earnings trajectory. Learn what drives revenue, how...
A 50-year-old professional earning $210,000 unveils a four-account plan to craft tax-free retirement income by 62, bl...
As Innodata prepares to unveil its Q1 2026 results, investors want clarity on growth drivers, margins, and the path t...